Palisade Bio (NASDAQ:PALI) Downgraded to “Sell” Rating by Wall Street Zen

Palisade Bio (NASDAQ:PALI) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

A number of other brokerages have also issued reports on PALI. LADENBURG THALM/SH SH raised shares of Palisade Bio to a “strong-buy” rating in a report on Thursday, June 25th. Weiss Ratings raised shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Wolfe Research began coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $2.00 target price on shares of Palisade Bio in a research note on Tuesday, June 30th. Finally, Oppenheimer set a $7.00 price target on shares of Palisade Bio in a report on Tuesday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Palisade Bio currently has an average rating of “Buy” and a consensus price target of $8.83.

Palisade Bio Price Performance

NASDAQ:PALI opened at $1.96 on Monday. The business’s 50-day simple moving average is $1.92 and its two-hundred day simple moving average is $1.92. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.85. The stock has a market cap of $340.22 million, a PE ratio of -1.94 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Sell-side analysts anticipate that Palisade Bio will post -0.25 earnings per share for the current fiscal year.

Insider Activity at Palisade Bio

In other news, CEO John David Finley sold 146,798 shares of Palisade Bio stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total transaction of $303,871.86. Following the completion of the sale, the chief executive officer directly owned 217,555 shares in the company, valued at approximately $450,338.85. This trade represents a 40.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Robert Jr. Baltera bought 30,000 shares of the stock in a transaction dated Tuesday, July 7th. The shares were bought at an average cost of $2.03 per share, with a total value of $60,900.00. Following the completion of the purchase, the director directly owned 416,904 shares of the company’s stock, valued at approximately $846,315.12. This trade represents a 7.75% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 125,000 shares of company stock worth $250,100 in the last quarter. 0.07% of the stock is owned by company insiders.

Institutional Investors Weigh In On Palisade Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PALI. Commodore Capital LP bought a new position in Palisade Bio in the 4th quarter worth about $26,896,000. BIT Capital GmbH bought a new stake in shares of Palisade Bio during the fourth quarter valued at approximately $717,000. Creek Drive Management Group LLC bought a new stake in shares of Palisade Bio during the fourth quarter valued at approximately $723,000. Perceptive Advisors LLC bought a new stake in shares of Palisade Bio during the fourth quarter valued at approximately $28,318,000. Finally, Artia Global Partners LP purchased a new stake in shares of Palisade Bio in the fourth quarter valued at approximately $4,682,000. Institutional investors own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.